In one of these clinical trials (NCT02111850), patients received a cyclophosphamide plus fludarabine regimen and a lymphodepleting regimen that targeted MAGE-A3 TCR for patients with metastatic BC, cervical cancer, renal cancer, urothelial cancer, and melanoma. Here, MAGEA3 is linked to cervical cancer.